Washington Health Institute | Clinical Research

Research site

(Unclaimed)

Location

1140 Varnum Street, NE PMB Suite 203, Washington, District of Columbia, United States of America

Site insights

Top conditions

Top treatments

Lenacapavir

Nucleos(t)Ide

Islatravir

Tenofovir Alafenamide

Budigalimab

TAF

Bictegravir

GS-6207

mRNA-1345

ABBV-382

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 16 total trials

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.

Active, not recruiting

Epstein-Barr Virus Infection

Biological: Placebo

Biological: mRNA-1195.1

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of do...

Active, not recruiting

HIV-1 Infection

Drug: BIC/FTC/TAF

Drug: Placebo to DOR/ISL

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologicall...

Active, not recruiting

HIV-1 Infection

Drug: ISL/LEN FDC

Drug: B/F/TAF

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection (PURPOSE 2)

The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of a...

Active, not recruiting

Pre-Exposure Prophylaxis of HIV Infection

Drug: Sub-cutaneous (SC) Lenacapavir (LEN)

Drug: PTM Oral LEN

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing re...

Active, not recruiting

HIV-1-infection

Drug: Optimized Background Regimen (OBR)

Drug: Oral Lenacapavir Placebo